IL7 and neoplasm: A study was conducted to genetically engineer TCR-T cells (7 × 19 P1A T) to express both IL-7 and CCL19, which resulted in complete tumour regression and prolonged survival in half of the mice after 7 × 19 P1A T treatment in a murine mast cell tumour P815 model [109].